Gilead sees encouraging results from shot to prevent HIV

Gilead (GILD) has seen encouraging results from its twice-yearly shot to prevent HIV. Yahoo Finance's Anjalee Khemlani reports more on the drug and how HIV treatments continue to be the largest contributor to the biotech company's market capitalization.

For more expert insight and the latest market action, click here to watch this full episode of Morning Brief.

This post was written by Melanie Riehl

Video Transcript

Gilead seen some really positive results from early trials with regards to an HIV drug.

Can you talk to me about that?

That's absolutely right.

It's a twice yearly shot has proven 100% efficacious in women in a study, a late stage study in Africa that's for women and adolescent girls.

This adds to Gilead sort of dominance in the HIV market, and they are known for their work with the pre exposure prophylaxis known as That's a huge market for them.

JP analysts saying that this is why, uh, Gilead's HIV portfolio is going to be and continues to be contributing to their market cap, being the largest contributor to their market cap, currently $85 billion.

And so that is something to keep an eye on when it gets approved.

How much it adds in fact, to the bottom line for the company.

100% efficacious.

My goodness.

O. Ok, All right.

The thing works.

Thank you.

Appreciate it